ArticleBriefings in bioinformatics2026
Gene set mediation analysis in high-dimensional epigenetic studies.
Article in Briefings in bioinformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Mediation analysis has significantly enhanced the elucidation of underlying epigenetic mechanisms by identifying mediators that influence the effect of an exposure on an outcome. In epigenomics research, the exponential increase in the dimensionality of mediators necessitates the development of advanced high-dimensional mediation models. Here we introduce a novel Gene Set High-Dimensional Mediation Analysis (gHDMA) model to understand the gene-level mediation role of DNA methylations, building upon our previous HDMA method. We begin our analysis by applying functional principal component analysis to capture gene variation signals across regions, thereby enhancing the model's statistical power. Following this, we employ the Sure Independence Screening method, based on Wilks' $\varLambda$-test, to efficiently reduce the dimensionality to a more manageable level, enabling high-dimensional inference. Our model is distinguished by its minimal reliance on stringent assumptions about the relationship between mediators and the outcome. Extensive simulation studies, by varying the type of basis function, the nature of the outcome variable, and the dimensionality of the gene region, demonstrate the robust performance of the gHDMA model. A corroborative case study further validates the methodology's efficacy. The gHDMA model emerges as a powerful analytical tool, with an enhanced capacity to identify genes characterized by hypermethylation or hypomethylation that mediate the effects of exposure on biological outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.